Tech Company M&A Transactions
Virdante Pharmaceuticals Acquisition
Virdante Pharmaceuticals was acquired by Momenta Pharmaceuticals. The transaction was announced on 12/7/2011. Momenta Pharmaceuticals disclosed that the acquisition price was $56 million.
Transaction Overview
Company Name
Acquired By
Announced On
12/7/2011
Transaction Type
M&A
Amount
$56,000,000
M&A Terms
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it has signed an agreement to acquire the Sialic Switch assets of Virdante Pharmaceuticals, Inc., including intellectual property and cell lines, relating to the sialylation of intravenous immunoglobulin (IVIG) and other proteins. Momenta made an upfront payment of $4.5 million and may make additional contingent milestone payments, which, if all development and regulatory milestones are achieved, will total $51.5 million.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
14 Cambridge Center Bldg 1
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Virdante is a privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Pat Gage
Chief Executive Officer
John Ripple
Browse more venture capital transactions:
Prev: 12/7/2011: Collective Intellect venture capital transaction
Next: 12/7/2011: Martini Media Network venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs